Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15.
about
Atypical hemolytic uremic syndromeOverview of C3 GlomerulopathyA new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injuryGenetic influences on plasma CFH and CFHR1 concentrations and their role in susceptibility to age-related macular degenerationFavorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation.Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains.Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.Complement factor H: using atomic resolution structure to illuminate disease mechanisms.aHUS caused by complement dysregulation: new therapies on the horizon.Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation.Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations.Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case.Exchange transfusion for neonate with haemolytic uremic syndrome.Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.Treatment options for C3 glomerulopathyKidney diseases caused by complement dysregulation: acquired, inherited, and still more to come.Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.Progress and Trends in Complement TherapeuticsNew approaches to the treatment of dense deposit disease.C3 glomerulopathy: consensus report.C3 glomerulopathy: clinicopathologic features and predictors of outcome.Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy.Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome.The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.2006 Council Lecture: Lancelot to the rescue: realizing the promise of genomic medicine.Local complement activation in aqueous humor in patients with age-related macular degeneration.An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.
P2860
Q21202864-92127F9A-3815-48EA-A43F-D508829BAF29Q26747262-59B340AC-906B-4B78-8B1F-925B0D0178EDQ26992169-68E31254-1E79-4CEB-95DB-1A9272361F70Q33356232-14B4FF39-0988-450B-95D0-AC923A25A285Q33372160-FA6A311C-A22C-4D4D-8285-E94FA0355813Q33375335-0A326DD6-0CA5-4988-8F57-0A71E6A17E6CQ33377727-CCFA31A4-503A-4AA3-85F3-37EB2AF9FF8EQ33381980-B4532FB9-7845-4798-91F2-967440FE7E23Q33382097-CAD5FB8F-FBED-4AB1-97E1-FCBB14B1A901Q33390198-70D77CF5-3171-4D5A-A251-9114C4E1A300Q33393107-6020847C-7937-40F0-9AEB-F91079ABBE7EQ33396013-231BE764-8DDF-4605-9111-755926EACA30Q33401621-8BA82F6F-16A4-481A-A6DF-34F5CD0B8555Q33429701-E2DF3593-11F1-45D6-9F9B-8E45490BB6E5Q33437488-DCF44504-E877-4094-9140-545FA35F573FQ34005720-3C38BEEE-4052-4031-8FDE-103E6DF35052Q35624672-A4BF07D0-79B9-46E9-A27A-4C59C21BF4BAQ36438860-90DB528E-1EB3-446E-9587-C3C60351A4B0Q36463266-DA818325-E186-435E-975F-CF91118A5CF5Q36479278-FDFB5532-400E-4408-80B5-5B53BBD4218DQ36860946-B7482AE8-B62B-4819-A960-D4D212CBCD15Q37348685-DDC7965E-7E2C-4E4B-A890-42646B263C90Q37426966-69585D0C-1369-433A-957B-788E82912AA0Q40865063-7294C860-40E2-4D99-BF43-5175D46A005BQ47251151-9A6EABC7-1ECA-4693-9C10-C5D8B6EDE412Q48241051-9B0C3CF4-CE31-4045-8D48-CEBC1F4D6048Q48555506-8B514FDF-0CAB-430B-A2DA-8F1500FB214FQ51166005-3D24C54E-82FD-4D41-AF39-FDABC09A8489Q51730313-A28B134F-B215-4B87-A3F9-8FE34BB1ED20
P2860
Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Successful plasma therapy for ...... nt cofactor protein domain 15.
@ast
Successful plasma therapy for ...... nt cofactor protein domain 15.
@en
type
label
Successful plasma therapy for ...... nt cofactor protein domain 15.
@ast
Successful plasma therapy for ...... nt cofactor protein domain 15.
@en
prefLabel
Successful plasma therapy for ...... nt cofactor protein domain 15.
@ast
Successful plasma therapy for ...... nt cofactor protein domain 15.
@en
P2093
P1476
Successful plasma therapy for ...... nt cofactor protein domain 15.
@en
P2093
Annic Weyersberg
Bernd Hoppe
Christoph Licht
Jacqueline Devenge
Ludwig Stapenhorst
Michael Kirschfink
Ruediger Waldherr
Stefan Heinen
P304
P356
10.1053/J.AJKD.2004.10.018
P577
2005-02-01T00:00:00Z